Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

47.98 +0.20 (+0.42%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
31 32 Next >
First Wave BioPharma To Acquire ImmunogenX To Bolster Gastrointestinal-Focused Pipeline
First Wave BioPharma Inc (NASDAQ: FWBI) has signed a non-binding term sheet to acquire ImmunogenX in an all-stock transaction with the combined company focused on advancing a pipeline for... 
Via Benzinga
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside. 
Via InvestorPlace
It's Almost 2024: 3 Top Stocks to Buy Before the New Year
You can pick these players up for a great price right now. 
Via The Motley Fool
French Drugmaker Sanofi Secures European Medicines Agency's Positive Opinion For Sleeping Sickness Treatment
Sanofi SA (NASDAQ: SNY), DNDi, and the HAT-r-ACC consortium  
Via Benzinga
3 Stocks to Buy Before 2024 That Can Set You Up For Life
These stocks are still relatively cheap, but don't expect them to stay that way for long. 
Via The Motley Fool
Why NASDAQ:SNY provides a good dividend, while having solid fundamentals.
Why SANOFI-ADR (NASDAQ:SNY) provides a good dividend, while having solid fundamentals. 
Via Chartmill
How Is The Market Feeling About Sanofi?
Via Benzinga
Is NASDAQ:SNY a Good Fit for Dividend Investing?
Is SANOFI-ADR (NASDAQ:SNY) a Good Fit for Dividend Investing? 
Via Chartmill
French Pharma Giant Sanofi Drops Rare Disease Drug Pact As Federal Trade Commission Puts Antitrust Obstacle
Sanofi SA (NASDAQ: SNY) said it is terminating the licensing agreement for Maze Therapeutics Inc.'s treatment for a rare genetic disorder after the Federal Trade Commission (FTC)  
Via Benzinga
Vanda Pharmaceuticals Acquires Rights To Multiple Sclerosis Drug From Johnson & Johnson's Company
Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has acquired U.S. 
Via Benzinga
Sanofi Lays Out Ambitious Plans To Bolster Its Pipeline, Highlights 12 Blockbuster Opportunities
Sanofi SA (NASDAQ: SNY) says it has 12 drugs in development with a blockbus 
Via Benzinga
IGM Biosciences Increases Focus On Autoimmune Diseases, Stops All Blood Cancer-Related Studies
IGM Biosciences Inc (NASDAQ: IGMS) said it will focus on two strategic areas: treating colorectal cancer using IgM death receptor 5 (DR5) agonist antibodies and treating autoimmune diseases using IgM... 
Via Benzinga
Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis
Merck KGaA (OTC: MKGAF) (OTC:  
Via Benzinga
Looking Into Sanofi's Recent Short Interest
Via Benzinga
Don't overlook NASDAQ:SNY—it's a hidden gem with strong fundamentals and an attractive price tag.
SANOFI-ADR (NASDAQ:SNY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Investor Demand for Clarity Grows Amid Sanofi's Strategic R&D Shift
Sanofi SA's (NASDAQ: SNY) CEO, Paul Hudson, is confronting mounting investor pressure as shareholders seek concrete details about the company's expanded R&D budget.  
Via Benzinga
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies... 
Via Benzinga
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
From Teva Pharmaceutical Industries Limited
Via Business Wire
2 Biotech Stocks You Can Buy and Hold for the Next Decade
These stocks aren't popular on the market right now, but investors shouldn't let that scare them off. 
Via The Motley Fool
Teva Pharma is the way to play the re-rise of generic drugs
Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth 
Via MarketBeat
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
Regeneron and Sanofi are partnered on Dupixent, a treatment for conditions tied to type 2 inflammation. 
Via Investor's Business Daily
Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that... 
Via Benzinga
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst
Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the  
Via Benzinga
US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges
The U.S. 
Via Benzinga
Major Buyout Firms Eye Sanofi's Consumer Health Division Spinoff Valued Over $20B
Sanofi SA (NYSE: SNY) has reportedly initiated talks with Rothschild & Co. to explore the possibility of spinning off its consumer health division, which could potentially value the business at over... 
Via Benzinga
Don't overlook NASDAQ:SNY—it's a hidden gem with strong fundamentals and an attractive price tag.
SANOFI-ADR (NASDAQ:SNY) is an undervalued gem with solid fundamentals. 
Via Chartmill
MarketBeat Week in Review – 11/6 - 11/10
Stocks closed the week with a strong rally, but the rally may reverse when investors get the latest information about inflation and retail stocks next week 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Pfizer and Sanofi shares fall, which one to scoop up?
Pharmaceutical stocks aren't having a banner year; notably, two large pharmaceutical companies recently plunged to 52-week lows 
Via MarketBeat
Exposures COVID-19
Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi
The company is looking to take on Regeneron and Sanofi's Dupixent in skin diseases. 
Via Investor's Business Daily
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.